Diagnostics on demand: a biosensor platform for multiplexed small molecule detection - small molecule detection is central in many biological, medical, and legal domains, including basic research,…

Diagnostics on demand: a biosensor platform for multiplexed small molecule detection - small molecule detection is central in many biological, medical, and legal domains, including basic research, clinical diagnostics, environmental monitoring, and workplace drug testing, among other applications. The most widely deployed diagnostics are immunoassay-based that utilize antibodies raised against ligand-protein conjugates. These easy-to-use assays enable applications as diverse as point-of-care diagnostics, in-home testing, and real-time environmental monitoring in the field. Although small molecule immunoassays are powerful, they are time-consuming and costly to develop because analogs of target molecules suitable for conjugation to immunogenic carrier proteins must be chemically synthesized. New methods that enable the routine creation of small molecule sensors using native molecules would radically increase the speed and decrease the costs required to develop new diagnostic tests. The proposed work addresses this by building a technology that will make developing new small molecule biosensors as easy and reliable as developing new antibodies. We will accomplish this using a versatile new sensing scaffold - the plant abscisic acid receptor PYR1. This receptor participates in chemical-induced dimerization with its binding partner, HAB1. We recently described a directed evolution pipeline for creating PYR1/HAB1 dimerization (PAIR) sensors and have created sensors for 116 small molecules, including 9-THC, 20 FDA-approved drugs, and dozens of natural products. These sensors can be used to create ligand-regulated genetic circuits, drive ligand-mediated reconstitution of split enzymes, and rapidly create sensitive diagnostic tests. While our platform is powerful, improvements in HIT rate, throughput, and the chemical space IT can access are needed to empower high-efficiency sensor development; to achieve this, we will combine strain engineering, high-throughput screening, and computational design. Our improved pipeline will be used for 1-step isolation of >1000 moderate-affinity sensors of FDA-approved drugs and other medically-relevant small molecules. 100 of these will be evolved to high-affinity (NM) sensors by subsequent rounds of directed evolution. In parallel, we will develop methods for converting these sensors into multiplexable diagnostics. The technology developed will deliver new tools and methods for developing sensors of user-specified molecules and open the door to user-specified chemical-regulated processes, will have broad biomedical relevance and will advance biomedical research and clinical and environmental diagnostics.